Most Read Articles
Stephen Padilla, 21 Nov 2018
Use of triple therapy consisting of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA) and inhaled corticosteroid (ICS) leads to a reduced rate of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) and better lung function and health-related quality of life compared with dual therapy (ICS and LABA or LAMA and LABA) or LAMA monotherapy, according to the results of a meta-analysis.

Nasal DNA methylation may predict response to systemic steroid treatment

27 Oct 2017

Methylation of nasal DNA may identify responders to acute systemic steroid treatment in paediatric patients with asthma, independent of single nucleotide polymorphisms (SNPs), according to a recent study.

The investigators divided 33 paediatric patients aged 5 to 18 years who had asthma exacerbations into two according to response to steroid treatment: good responders (n=15; median age 8.0 years; 67 percent male) and poor responders (n=18; median age 6.5 years; 67 percent male). Nasal samples collected at presentation (T0) and at 18 to 24 hours after (T1) were used to determine DNA methylation.

DNA methylation at CpG sites did not change between T0 and T1 in poor responders. On the other hand, five CpG sites in good responders showed nominally significantly altered DNA methylation, which did not reach genome-wide significance.

Using data from the T1 nasal samples, 85 CpG sites showed differential DNA methylation between the groups and were able to determine poor from good systemic steroid treatment responders. The level of methylation in 32 of these sites was enough to completely distinguish between the two groups.

Pathway analysis showed that some of these 32 sites were in the promoter of the LDHC gene, which codes for lactate dehydrogenase. At these sites, methylation correlated negatively with gene expression.

“Interestingly, quite a few of these CpG sites can be disrupted by the presence of certain common SNPs; in most of these sites, DNA methylation was altered along with their genotypes,” researchers said.

“Taken together, our findings suggest that epigenetic mechanisms underlie the heterogeneous responses to systemic steroid treatment, in part driven by genetic variations present at CpG sites,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 21 Nov 2018
Use of triple therapy consisting of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA) and inhaled corticosteroid (ICS) leads to a reduced rate of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) and better lung function and health-related quality of life compared with dual therapy (ICS and LABA or LAMA and LABA) or LAMA monotherapy, according to the results of a meta-analysis.